Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described molecular glue compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers ...

The drug is based on an antibody component targeting the CD33 receptor linked to a molecule that breaks down GSPT1, an intracellular protein that is thought to promote the proliferation ...